Holen Sie sich die Stockscreener-App
1.90
5.47%
-0.11
Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data - MSN
Entera Bio shares hold Buy rating on OXM study success By Investing.com - Investing.com South Africa
Entera Bio shares hold Buy rating on OXM study success By Investing.com - Investing.com Australia
Entera Bio shares hold Buy rating on OXM study success - Investing.com
Entera Bio's (ENTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com Australia
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com South Africa
Entera Bio and OPKO Health report promising obesity treatment study - Investing.com
Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders - XM
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com UK
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders - Yahoo Finance
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? - MSN
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? - MSN
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Yahoo Finance
Entera Bio to Participate in Upcoming Investor and Scientific Conferences - GlobeNewswire
Entera Bio to Participate in Upcoming Investor and Scientific Conferences - StockTitan
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy - Yahoo Finance
Entera Bio Ltd. Forecasted to Earn Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:ENTX) - Defense World
Entera Bio Ltd. to Post Q3 2024 Earnings of ($0.05) Per Share, HC Wainwright Forecasts (NASDAQ:ENTX) - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 51.0% in July - MarketBeat
Entera Bio (NASDAQ:ENTX) Releases Earnings Results - MarketBeat
Entera Bio's (ENTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Entera Bio (NASDAQ:ENTX) - Defense World
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - GlobeNewswire
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - wallstreet:online
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates - StockTitan
Virtu Financial LLC Invests $37,000 in Entera Bio Ltd. (NASDAQ:ENTX) - Defense World
Entera Bio Ltd expected to post a loss of 6 cents a shareEarnings Preview - XM
The 10 Best Biotech Stocks Under $5 To Buy For September 2024! - The Stock Dork
Entera Bio shareholders approve executive compensation, board appointments - Investing.com
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual MeetingKey SABRE Update Also Expected - StockTitan
Entera Bio (NASDAQ:ENTX) Trading Up 1.9% - MarketBeat
Entera Bio (NASDAQ:ENTX) Stock Price Up 1.9% - Defense World
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual MeetingKey SABRE Update Also Expected - Yahoo Finance
Entera Bio (NASDAQ:ENTX) & Vericel (NASDAQ:VCEL) Financial Survey - Defense World
Short bowel syndrome Market Positive Outlook: Phase Bio , Orphan Technologies , Zealand Pharma - Newstrail
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years - Markets Insider
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Simply Wall St
Entera Bio (NASDAQ:ENTX) Trading 6% Higher - MarketBeat
Entera Bio (NASDAQ:ENTX) Stock Price Up 6% - Defense World
Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for ... - Barchart
Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich - Markets Insider
Head to Head Contrast: Entera Bio (NASDAQ:ENTX) and HilleVax (NASDAQ:HLVX) - Defense World
Aegis Capital initates Entera Bio Ltd (ENTX) rating to a Buy – Knox Daily - Knox Daily
Entera Bio Ltd (ENTX)'s stock rises to 2.11 per share – US Post News - US Post News
Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo New Zealand News
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards? - Yahoo Lifestyle Singapore
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 - Markets Insider
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar - Markets Insider
Entera Bio (NASDAQ:ENTX) Receives “Buy” Rating from HC Wainwright - Defense World
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU - Zacks Investment Research
Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year? - Zacks Investment Research
Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year? - Yahoo Finance Australia
Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with ... - Yahoo Finance
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study - Zacks Investment Research
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus - Zacks Investment Research
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal - Zacks Investment Research
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Expands By 260.8% - MarketBeat
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why - Zacks Investment Research
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data - Zacks Investment Research
Upward Trajectory: Entera Bio Ltd (ENTX) Posts a Gaine, Closing at 2.32 – DWinneX - The Dwinnex
Analyzing Entera Bio (NASDAQ:ENTX) & Halozyme Therapeutics (NASDAQ:HALO) - Defense World
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data - Zacks Investment Research
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):